SIMCERE PHARMA (02096) surged over 6% in the morning session. As of press time, the stock was up 6.02% to HK$14.08, with a turnover of HK$241 million.

On the news front, SIMCERE PHARMA released its interim results, showing operating revenue increased 15.1% year-on-year to 3.585 billion yuan in the first half, with adjusted net profit of 651 million yuan, up 21.1% year-on-year. According to the report, the company now has ten marketed innovative drugs, with innovative drug revenue reaching 2.776 billion yuan, up 26% year-on-year, accounting for 77.4% of total revenue for the first time, surpassing three-quarters.

In the first half of 2025, two innovative drugs received marketing approval, two candidate drugs entered the NDA review stage, and two other self-developed clinical-stage products achieved innovative overseas licensing agreements, demonstrating outstanding innovation transformation results.

CICC believes that SIMCERE PHARMA's first-half performance exceeded market expectations, primarily driven by the innovative drug business. In H1 2025, the company's innovative drug business revenue reached 2.776 billion yuan, up 26.0% year-on-year, with the revenue proportion increasing 3.1 percentage points from 74.3% in 2024 to 77.4%. Innovative drugs such as Cisaila and SINOT sublingual tablets are rapidly scaling up, and the company expects Keweike (Dalizuresib) to officially launch in H2 2025. Meanwhile, three of the company's products (Suvizumab, Dalizuresib, and SINOT sublingual tablets) were included in the recent commercial insurance catalog, which is expected to drive continued rapid growth in innovative drug revenue.